O-32: Effects of Intrauterine Injection of Recombinant Human Chorionic Gonadotropin before Embryo Transfer on Outcome of In Vitro Fertilization/Intracytoplasmic Sperm Injection: A Randomized Clinical Trial

Background: To evaluate the effectiveness of intrauterine injection of recombinant human chorionic gonadotropin (rhCG) before embryo transfer (ET). Materials and Methods: In this randomized placebocontrolled clinical trial, a total number of 182 infertile patients undergoing their first in vitro fertilization/intracytoplasmic sperm injection (IVF-ICSI) were randomly assigned to receive 250 μg intrauterine rhCG (n=84) or placebo (n=98) before ET. The implantation and pregnancy rates were compared between groups. Results: Patients who received intrauterine rhCG before ET had significantly higher implantation (36.9% vs. 22.4%; p=0.035), clinical pregnancy rates (34.5% vs. 20.4%; p=0.044) and ongoing pregnancy rate (32.1% vs. 18.4%; p=0.032) when compared to those who received placebo. The abortion (2.4% vs. 2.0%; p=0.929) and ectopic pregnancy rates (1.2% vs. 1.0%; p=0.976) were comparable between groups. Conclusion: Intrauterine injection of 250 μg of rhCG before ET significantly improves the implantation and pregnancy rates in IVF/ICSI.